Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Immunol. Nov 27, 2014; 4(3): 130-140
Published online Nov 27, 2014. doi: 10.5411/wji.v4.i3.130
Published online Nov 27, 2014. doi: 10.5411/wji.v4.i3.130
Subcutaneous and sublingual immunotherapy: Where do we stand?
Ayfer Yukselen, Clinic of Pediatric Allergy and Immunology, Gaziantep Children Hospital, 27560 Gaziantep, Turkey
Seval Guneser Kendirli, Clinic of Pediatric Allergy and Immunology, Cukurova University Faculty of Medicine, 01330 Balcali, Adana, Turkey
Author contributions: The collection of documents, the review of articles published up to day about immunotherapy and writing of the manuscript were made by Yukselen A; Kendirli SG consulted and contributed to the manuscript with her valuable comments.
Correspondence to: Ayfer Yukselen, MD, Clinic of Pediatric Allergy and Immunology, Gaziantep Children Hospital, Osmangazi mah., Sehitkamil, 27560 Gaziantep, Turkey. ayfyukselen@gmail.com
Telephone: +90-342-2200072 Fax: +90-342-2200072
Received: March 29, 2014
Revised: May 1, 2014
Accepted: July 12, 2014
Published online: November 27, 2014
Revised: May 1, 2014
Accepted: July 12, 2014
Published online: November 27, 2014
Core Tip
Core tip: Specific allergen immunotherapy is the unique treatment method capable of changing the natural course of allergic disease. Both Subcutaneous (SCIT) and sublingual (SLIT) may act as efficient treatment options in patients with allergic rhinoconjunctivitis and asthma. In this paper, we reviewed clinical efficacy and safety of both SCIT and SLIT in allergic respiratory diseases by discussing recent studies.